{
  "slug": "adimab",
  "name": "Adimab",
  "description": "Adimab is a therapeutic antibody discovery and protein engineering platform that partners with biopharma companies to advance therapeutic proteins from concept to clinic. They offer a full suite of solutions including IgGs, HCAbs, multispecifics, and TCRs, leveraging a proprietary yeast-based platform for high specificity, stability, and developability.",
  "url": "https://optimly.ai/brand/adimab",
  "websiteUrl": "https://adimab.com/",
  "logoUrl": "https://logo.clearbit.com/adimab.com",
  "baiScore": null,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Therapeutic Antibody and Protein Discovery Services",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-18T07:00:49.356Z",
  "verifiedVitals": {
    "website": "https://adimab.com",
    "category": "Biopharmaceutical antibody discovery and engineering",
    "what_it_does": "Adimab provides a proprietary yeast-based platform for therapeutic antibody discovery and protein engineering, advancing therapeutic proteins from concept to clinic. Their capabilities include delivering IgGs, HCAbs, multispecifics, and TCRs.",
    "primary_audience": "Biopharma companies and partners seeking therapeutic antibody discovery and engineering solutions.",
    "core_product": "The Premier Antibody Discovery And Engineering Platform, offering full suite antibody discovery solutions including antibody discovery, antibody engineering, multispecific antibodies and T cell engagers, and protein and TCR engineering.",
    "pricing_model": {
      "kind": "custom",
      "detail": "Adimab offers flexible collaboration models, including funded discovery, platform transfer, and non-exclusive programs."
    },
    "parent_ownership": null
  },
  "intentTags": {
    "problemIntents": [
      "Challenges in advancing therapeutic proteins from concept to clinic",
      "Need for highly specific, stable, and developable therapeutic antibodies",
      "Inefficiency in therapeutic antibody production",
      "Difficulties in engineering multispecific antibodies and T cell engagers",
      "Requirement for AI-guided engineering of non-antibody proteins"
    ],
    "solutionIntents": [
      "Therapeutic antibody discovery platform",
      "Protein engineering services",
      "Multispecific antibody development",
      "T cell engager engineering",
      "Access to synthetic and immune libraries for antibody discovery",
      "High-throughput screening and hit characterization for biologics",
      "Partnership models for drug discovery and development"
    ],
    "evaluationIntents": [
      "Evaluate antibody developability and stability platforms",
      "Assess track record of biopharma partnerships and clinical programs",
      "Compare antibody discovery efficiency and reliability",
      "Review multispecific and TCR engineering capabilities",
      "Analyze flexibility of collaboration and licensing models"
    ]
  },
  "businessProfileClaims": [],
  "timestamp": 1787122179607
}